Actively Recruiting

Age: 18Years +
All Genders
NCT07154524

Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Led by University of Ulm · Updated on 2025-09-11

140

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

Sponsors

U

University of Ulm

Lead Sponsor

F

Fresenius Medical Care Deutschland GmbH

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to intravenous immunoglobulins (IVIg) and methyl-prednisolone (MP). For this purpose, approximately 140 patients with CIDP will be included within the framework of the German multicenter network "Kompetenznetz Peripherer Nerv" (KKPNS). The study will be purely observational. IA will be performed as an escalation therapy, i.e., in patients who did not respond to IVIg and/or MP treatment. Patients will be included in the study during ongoing IVIg or MP treatment and switched to IA during the 18-month observation period in case of an insufficient response. IA will be performed according to the therapeutic scheme of each participating center. A non-mandatory recommendation for number of sessions, treatment volumes, and frequency will be given (see below). Six-month follow-up visits including collection of standardized clini-cal data will be performed.

CONDITIONS

Official Title

Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of CIDP based on the EAN/PNS Guidelines on Diagnosis and Treatment of CIDP
  • Age 18 years or older
  • Willing and capable of giving written informed consent
  • Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Ulm

Ulm, Baden-Wurttemberg, Germany, 89081

Actively Recruiting

Loading map...

Research Team

J

Johannes Dorst, Prof. Dr.

CONTACT

Z

Zeynep Elmas

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here